Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program
- 7 February 2008
- journal article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (6), 1190-1197
- https://doi.org/10.1002/pbc.21450
Abstract
Background SCH 717454 (19D12) is a fully human antibody directed against the insulin‐like growth factor 1 receptor (IGF‐1R), which is implicated in the growth and metastatic phenotype of a broad range of malignancies. The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures SCH 717454 was tested against the PPTP in vitro panel at concentrations ranging from 0.01 to 100 nM and was tested against the PPTP in vivo panel at a dose of 0.5 mg per mouse administered twice weekly for 4 weeks via intraperitoneal injection. Results SCH 717454 was ineffective at retarding growth of cell lines in the in vitro panel. In vivo, SCH 717454 significantly increased event‐free survival in 20 of 35 (57%) solid tumor xenograft models with tumor regressions in one Ewing sarcoma model (complete response) and 2 osteosarcoma models (maintained complete responses). Using the time to event activity measure, SCH 717454 had intermediate (n = 9) or high (n = 1) activity against 31 evaluable solid tumor xenografts, including xenografts from the rhabdoid tumor, Ewing, rhabdomyosarcoma, glioblastoma, neuroblastoma, and osteosarcoma panels. SCH 717454 showed little activity against the 8 xenografts of the acute lymphoblastic leukemia panel. Conclusions SCH 717454 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels. Further characterization of the molecular predictors of response and of the activity of combinations of SCH 717454 with other anticancer agents are anticipated. Pediatr Blood Cancer 2008;50:1190–1197.This publication has 48 references indexed in Scilit:
- EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3Molecular and Cellular Biology, 2004
- IGF‐1 receptor contributes to the malignant phenotype in human and canine osteosarcomaJournal of Cellular Biochemistry, 2004
- Insulin-like Growth Factor (IGF) I Down-Regulates Type 1 IGF Receptor (IGF 1R) and Reduces the IGF I Response in A549 Non-Small-Cell Lung Cancer and Saos-2/B-10 Osteoblastic Osteosarcoma CellsExperimental Cell Research, 2001
- Association of EWS-FLI1 Type 1 Fusion with Lower Proliferative Rate in Ewing's SarcomaThe American Journal of Pathology, 2000
- The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft modelsCancer Chemotherapy and Pharmacology, 2000
- High frequency of inactivation of the imprintedH19 gene in ?sporadic? hepatoblastomaInternational Journal of Cancer, 1999
- Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma.JCI Insight, 1994
- Insulin-like growth factor II-mediated proliferation of human neuroblastoma.JCI Insight, 1991
- Suramin Blockade of Insulinlike Growth Factor I-Stimulated Proliferation of Human Osteosarcoma CellsJNCI Journal of the National Cancer Institute, 1990
- The expression of insulin-like growth factor I and insulin-like growth factor II genes in the human fetal and adult brain and in gliomaNeuroscience Letters, 1988